Uncategorized

Santersus AG is proud to be recognized as a top innovator and to be granted a presentation slot at the transCampus Partnership 10 year Anniversary Event in London on February 13, 2023. The transCampus partnership, which is overseen by joint Dean, Professor Stefan Bornstein includes joint professorships, administrative structures and training programmes for students from the …

Santersus AG Presented at transCampus Partnership Event in London Read More »

A study, published on Aug. 12 in Nature, identifies several molecular patterns that recognise pattern recognition receptors. Pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) are commonly used terminologies to classify molecules originating from pathogen and endogenous molecules, respectively, to heighten the immune response in sepsis. The authors focused on a subgroup of endogenous molecules …

Chromatin-Associated Molecular Patterns (CAMPs) in sepsis Read More »

A recent publication demonstrates the close connection between immune dysfunction in T cells and neutrophils that can be targeted by interfering with microbial sequestration in the spleen or by eliminating circulating chromatin. The presence of G-CSF and circulating histones in many conditions suggests that they may be critical drivers of immune dysfunction that could be …

Microbe capture by splenic macrophages triggers sepsis via T cell-death-dependent neutrophil lifespan shortening Read More »

A new publication highlights a potential role of neutrophils in pulmonary long COVID. Individuals who had persistent pulmonary symptoms, showed a neutrophil-associated inflammatory phenotype and evidence of NETs in blood. The publication was published on Nov. 16 in Science Translational Medicine. It is also co-authored by Dr Andrew Aswani – our Chief Medical Officer. Interstitial lung disease …

A persistent neutrophil-associated immune signature characterizes post–COVID-19 pulmonary sequelae Read More »

A new publication suggests that deficient DNA clearance is linked to increased mortality in individuals with severe COVID-19 pneumonia. The publication was accepted on Nov. 15 and will soon appear in Immunity. It is co-authored by Prof Sascha David, Dr Klaus Stahl and Dr Christian Bode, who will take part in the future of Santersus as Principle Investigators …

Functional proteomic profiling links deficient DNA clearance with increased mortality in individuals with severe COVID-19 pneumonia  Read More »

Physiology and biological impact of removing circulating cell-free DNA/Neutrophil Extracellular Trap (cfDNA/NET) on modifying lung injury at University of Edinburgh on FindAPhD.com In critically ill patients, cell free DNA (cfDNA), a danger signal capable of initiating intense innate immune responses, is measurable in circulation. Higher levels of cfDNA in circulation is associated with greater inflammatory …

Santersus AG is excited to announce the commencement of its PhD program with the University of Edinburgh. Read More »

Santersus AG, a privately held therapeutic apheresis company, announced today that their medical device product, NucleoCapture, has been granted designation as a Breakthrough Device by The Center for Devices and Radiological Health (CDRH) of the US Food and Drug Administration (FDA). The indication cited in the breakthrough designation is as an adjunctive treatment to antibiotics …

Santersus NucleoCapture Technology Designated as a Breakthrough Device for the Treatment of Sepsis by the US FDA Read More »

It was shown that circulating NETs might support Inflamm-ageing chronic low grade inflammation typical of ageing, being common biological factor responsible for the decline and the onset of disease in the elderly. At Santersus, we are investigating the use of NucleoCapture to prevent inflamm-ageing and slow down functional decline in the elderly.